ArticleAnalytical chemistry2026
Label-Free Evaluation of Advanced Glycation End Products by a Comprehensive Biophysical Analysis.
Article in Analytical chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
Nonenzymatic glycation is a post-translational modification of proteins, leading to the formation of advanced glycation end products (AGEs) implicated in diabetes, neurodegenerative disorders (NDDs), and aging-related complications. The sensitive and precise detection of protein-bound AGEs is essential for comprehending their pathological implications. Conventional detection methods for AGEs have several drawbacks, such as being expensive and time-consuming, complex sample preparation steps, etc. Further, AGEs' structural complexity and heterogeneity affect their accurate determination. Therefore, we introduce an autofluorescence-based methodology (LED-induced autofluorescence) for detecting and tracking the formation of AGEs on proteins using a low-power fiber-coupled near-UV LED (340 nm) and a blue LED (430 nm) as excitation sources covering the heterogeneous excitation maxima of multiple AGEs that form on proteins. The device captures the wide range of AGEs-specific autofluorescence signatures without the interference of protein autofluorescence, revealing their heterogeneous composition on proteins. The device demonstrated high sensitivity in detecting standard pentosidine (3.66 pg/μL) at 340 nm excitation, while enabling effective monitoring of the formation and progression of clinically relevant AGEs such as pentosidine, argpyrimidine, vesperlysine (A, B, and C), etc., generated on various structurally distinct glycated proteins in vitro. While noninvasive diabetes risk assessment and diagnosis based on AGEs fluorescence is gaining growing attention, the use of low-power, cost-effective light-emitting diodes (LEDs) as excitation sources offers significant advantages. Their stable power output ensures high reproducibility, enabling a rapid and reliable approach to assessing protein glycation, facilitating the routine monitoring of accumulation of AGEs, and advancing research addressing glycation-related complications in diabetes, aging, and NDDs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.